Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
- 1 January 2002
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 42 (1) , 24-29
- https://doi.org/10.1177/0091270002042001002
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trialPharmacogenetics, 2000
- Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency dataPharmacogenetics, 1999
- Decreased capacity for debrisoquine metabolism among black TanzaniansPharmacogenetics, 1999
- Investigation of terbinafine as a CYP2D6 inhibitor in vivoClinical Pharmacology & Therapeutics, 1999
- Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3AJournal of Pharmacy and Pharmacology, 1998
- Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationPharmacogenetics, 1998
- Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective studyEuropean Journal of Clinical Pharmacology, 1997
- The hypoalgesic effect of tramadol in relation to CYP2D6*Clinical Pharmacology & Therapeutics, 1996
- Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylationClinical Pharmacology & Therapeutics, 1985
- Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in GhanaiansClinical Pharmacology & Therapeutics, 1985